Myeloid growth factor for LGL – pro
Large granular lymphocyte (LGL) leukemia is characterized by a clonal expansion of either CD3+ cytotoxic T or CD3− NK cells. Prominent clinical features of T-LGL leukemia include neutropenia, anemia and rheumatoid arthritis (RA). The majority of these patients eventually need treatment because of severe or symptomatic neutropenia, anemia, or RA. No standard therapy has been established because of the absence of large prospective trials. A recent review says: “one might consider a single G-CSF injection to test the potential myeloid progenitor mobilization for a patient with asymptomatic neutropenia. If a positive response occurs, G-CSF could be administered at the time of neutropenic fever along with appropriate antibiotics.” Other reviews, such as Sokol et al are more generous about using GSDF prophylactically and do recommend it.
Thierry Lamy and Thomas P. Loughran Jr, How I treat LGL leukemia. March 10, 2011; Blood: 117 (10)
Mohan SR1, Maciejewski JP.Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol. 2009 Jan;16(1):27-34.
Lubomir Sokol, Thomas P. Loughran, Jr.Large Granular Lymphocyte Leukemia. The Oncologist 2006; 11:263-273;